BioPharma Financial Statements From 2010 to 2026
| BOPCFDelisted Stock | USD 0.92 0.00 0.00% |
Check BioPharma Credit financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioPharma Credit's main balance sheet or income statement drivers, such as , as well as many indicators such as . BioPharma financial statements analysis is a perfect complement when working with BioPharma Credit Valuation or Volatility modules.
BioPharma |
BioPharma Credit PLC Company Operating Margin Analysis
BioPharma Credit's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current BioPharma Credit Operating Margin | 0.85 % |
Most of BioPharma Credit's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioPharma Credit PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, BioPharma Credit PLC has an Operating Margin of 0.8521%. This is much higher than that of the sector and significantly higher than that of the Operating Margin industry. The operating margin for all United States stocks is notably lower than that of the firm.
BioPharma Credit PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioPharma Credit's current stock value. Our valuation model uses many indicators to compare BioPharma Credit value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioPharma Credit competition to find correlations between indicators driving BioPharma Credit's intrinsic value. More Info.BioPharma Credit PLC is rated below average in return on equity category among its peers. It is rated fourth in return on asset category among its peers reporting about 0.62 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for BioPharma Credit PLC is roughly 1.60 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioPharma Credit's earnings, one of the primary drivers of an investment's value.About BioPharma Credit Financial Statements
BioPharma Credit stakeholders use historical fundamental indicators, such as BioPharma Credit's revenue or net income, to determine how well the company is positioned to perform in the future. Although BioPharma Credit investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioPharma Credit's assets and liabilities are reflected in the revenues and expenses on BioPharma Credit's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioPharma Credit PLC. Please read more on our technical analysis and fundamental analysis pages.
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company was incorporated in 2016 and is based in Exeter, the United Kingdom. Biopharma Credit is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in BioPharma Pink Sheet
If you are still planning to invest in BioPharma Credit PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPharma Credit's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |